Merit Medical Systems stock (US59001A1025): valuation metrics in focus after recent trading around the mid-60 USD range

Merit Medical Systems shares continue to trade on Nasdaq in the mid-60 USD area, keeping valuation metrics such as the P/E multiple and market capitalization in focus for investors tracking the United States-based medical device group.

Merit Medical Systems shares, listed on Nasdaq under the ticker MMSI in the United States, have recently been changing hands in the mid-60 USD range, with some data providers citing levels around USD 61.85 to USD 64.52 per share, underscoring a market capitalization in the area of USD 3.7 billion as of late May 2026 according to Robinhood and Financhill data.Robinhood as of 05/28/2026Financhill as of 05/28/2026

The stock remains actively traded on the US market, giving investors in the home country direct exposure to the Utah-based medical device manufacturer, while also seeing activity on various European platforms that offer access to Nasdaq-listed shares for German-speaking investors.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Merit Medical Systems
• Sector/industry: Medical devices, cardiovascular and specialty therapeutics
• Headquarters/country: South Jordan, United States
• Core markets: United States, Europe, selected international healthcare markets
• Key revenue drivers: Cardiovascular and endoscopy-related disposable devices, diagnostic and therapeutic catheters, and specialized products for interventional procedures
• Home exchange/listing venue: Nasdaq (MMSI)
• Trading currency: USD

Merit Medical Systems: core business model

Merit Medical Systems concentrates on designing and manufacturing single-use medical devices for interventional cardiology, radiology, and endoscopy, with sales driven largely by hospitals and healthcare providers that use its disposable products in minimally invasive cardiovascular and other specialty procedures.

Valuation metrics and multiples for Merit Medical Systems

Recent market data place Merit Medical Systems on a forward-looking valuation that reflects its positioning as a mid-cap US medical device player, with a price-to-earnings ratio cited around 27 times based on a share price of approximately USD 61.85 and a market capitalization of roughly USD 3.69 billion according to Robinhood.Robinhood as of 05/28/2026

While detailed enterprise-value-based metrics and dividend yields are not always disclosed in summary data, investor-focused platforms such as Financhill show the stock score around the low-40s on their internal scale at a share price near USD 64.52, placing the name in a mid-range valuation bracket compared with its historical profile.Financhill as of 05/28/2026

For investors looking at earnings quality as part of the valuation picture, MarketBeat data referencing the latest reported quarter indicate that Merit Medical Systems generated a return on equity of about 13.54 percent and a net margin close to 9.03 percent, with quarterly revenue growth of 7.4 percent year-on-year, suggesting that the earnings base supporting current multiples stems from a combination of mid-single-digit to high-single-digit top-line expansion and moderate profitability.MarketBeat as of 05/28/2026

According to the same MarketBeat coverage, the consensus analyst stance on Merit Medical Systems stands at a "Moderate Buy" rating with an average price target around USD 92.80 per share, implying that, on aggregate, research houses see room between the current mid-60 USD price area and their longer-term valuation models, although individual targets and assumptions vary by institution.MarketBeat as of 05/28/2026

As far as capital returns are concerned, available summaries do not highlight a notable cash dividend for the stock, and the focus for Merit Medical Systems valuation appears instead to be on growth in earnings and cash flow from its portfolio of cardiovascular and endoscopy devices, rather than on yield metrics, which is typical for many US-listed mid-cap growth-oriented medical technology names.

Looking at ownership dynamics that can intersect with valuation, MarketBeat reports that institutional investors such as Fisher Asset Management have been actively adjusting positions, with a filing dated 05/28/2026 showing Fisher trimming its stake by 16,606 shares, which is a relatively small portion compared with total volume but still offers a window into how large asset managers calibrate exposure as the stock trades around the current valuation range.MarketBeat as of 05/28/2026

On the German-speaking side of the investor base, the Nasdaq listing can typically be accessed via electronic platforms such as Tradegate or gettex with euro-quoted prices that track the underlying US line, allowing investors in Germany, Austria, and Switzerland to reflect the same valuation discussions in their local currency even though the primary trading and corporate reporting remain centered in the United States.

Conclusion

With Merit Medical Systems stock trading on Nasdaq in the mid-60 USD band and sporting a P/E multiple near the high-20s on recent figures, valuation metrics remain an important lens through which investors in the United States and abroad view the company. The combination of mid- to high-single-digit revenue growth, double-digit return on equity, and consensus analyst expectations that cluster above the current share price level forms the backdrop for ongoing debate about how the stock should be priced within the medical device peer group. As long as trading liquidity on the US market stays healthy and institutional investors continue to fine-tune their holdings, valuation indicators such as earnings multiples, market capitalization, and implied upside or downside to consensus targets are likely to stay at the center of attention for Merit Medical Systems.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.